More recently, similar safety findings were reported by the pivotal phase 3 LUNAR study of TTFields therapy applied to the thorax with a PD-(L)1 inhibitor or docetaxel in 133 patients with metastatic NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.